[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.
about
Positron Emission Tomography in Breast CancerThe application of positron emission tomography (PET/CT) in diagnosis of breast cancer. Part II. Diagnosis after treatment initiation, future perspectivesRole of positron emission tomography for the monitoring of response to therapy in breast cancerPhosphorylation status of thymidine kinase 1 following antiproliferative drug treatment mediates 3'-deoxy-3'-[18F]-fluorothymidine cellular retentionIntroduction to the analysis of PET data in oncology.The σ2 receptor: a novel protein for the imaging and treatment of cancer.Quantitative assessment of dynamic PET imaging data in cancer imaging.Assessment of tumor response to chemotherapy in patients with breast cancer using (18)F-FLT: a meta-analysis.Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.Metabolically active tumour volume segmentation from dynamic [(18)F]FLT PET studies in non-small cell lung cancer.PET Tracers for Clinical Imaging of Breast Cancer.A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688Molecular imaging probes for diagnosis and therapy evaluation of breast cancerMonitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging.Evaluation of 18F-fluorothymidine positron emission tomography ([18F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer.Innovation in cancer imaging.Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response.Predicting tumour response.FLT PET-CT in evaluation of treatment response.DW-MRI and (18) F-FLT PET for early assessment of response to radiation therapy associated with hypoxia-driven interventions. Preclinical studies using manipulation of oxygenation and/or dose escalation.3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.Advantages of (18)F FDG-PET/CT over Conventional Staging for Sarcoma Patients.¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3´-deoxy-3´-fluorothymidine PET: a pilot study.[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.Imaging Tumor Proliferation in Breast Cancer: Current Update on Predictive Imaging BiomarkersImaging of molecular target modulation in oncology: challenges of early clinical trials
P2860
Q26768486-4F0322BE-5035-4E54-BEEF-270E26D181E9Q28077678-D589FF64-03D1-48CD-A102-BDD16C9D530EQ28080621-7F9243E1-A0BD-4EB3-85EE-461CFE128BD1Q28540476-750FEB9B-0792-4E16-86C5-CB20C9A168EDQ30594766-D407A908-5C97-4361-97BB-5270326FE1ECQ33782364-B70E9F5A-24A0-4FCA-8708-C1DD4D2DCD83Q34346931-3B248145-6CD5-41D4-AD42-A7FEFC7AD53FQ34452741-9CB6D51A-BB4D-447D-B65D-3FF279BB9F63Q34744444-BE32D539-3377-4AA0-9E45-DE1B53820874Q35537570-1A95B172-A45C-4984-A911-9D7579E940FFQ36221080-C89730D7-F05B-4597-962F-EC359358B51BQ36533964-5C303AD7-A56F-42AF-9D07-EF85A862555BQ36692448-26F17CF3-D34C-4EA5-A80B-A01B76E86187Q37326605-0907242F-F0B0-4674-ACCA-F9883F5AF788Q37418581-E08B5F14-E876-43E2-A75D-6A39C412CA65Q38005915-23831165-484A-43BD-AEC3-65599E3CA4C7Q38090509-9D05A0C1-9D26-40B0-95D7-AA70F3550300Q38141699-1481E7C1-EDA8-4146-9F34-83733BF2D114Q38206772-C9A6FED5-3530-45BC-A6AD-331D52EFA23AQ38780973-66F0139F-4546-4E69-8840-59D42DA2EC91Q41448654-D83C1ECF-DB28-44E4-B965-64DFF264EDBFQ47831312-F12D86C7-DFB2-4BAA-BC3D-470A951DDB91Q51009203-41E8FE7D-10BE-4BB6-8304-2706877AE822Q53169426-6F2A3238-595C-4CD6-A541-92AA4E80AC42Q55286904-B3B24829-0E18-4F8B-9456-1FF13E6A6D70Q57110625-E8DDA80C-0C44-49C0-9951-C377F1B494C5Q57758791-6E4D2308-2B67-4550-88F4-B1B517520779
P2860
[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
[18F]-3'Deoxy-3'-fluorothymidi ...... cancer response to docetaxel.
@en
[18F]-3'Deoxy-3'-fluorothymidi ...... cancer response to docetaxel.
@nl
type
label
[18F]-3'Deoxy-3'-fluorothymidi ...... cancer response to docetaxel.
@en
[18F]-3'Deoxy-3'-fluorothymidi ...... cancer response to docetaxel.
@nl
prefLabel
[18F]-3'Deoxy-3'-fluorothymidi ...... cancer response to docetaxel.
@en
[18F]-3'Deoxy-3'-fluorothymidi ...... cancer response to docetaxel.
@nl
P2093
P1476
[18F]-3'Deoxy-3'-fluorothymidi ...... cancer response to docetaxel.
@en
P2093
Adil Al-Nahhas
Amarnath Challapalli
Eric O Aboagye
Jimmy Jacob
Justin Stebbing
Kaiyumars B Contractor
Laura M Kenny
Lula Rosso
R Charles Coombes
Rizvana Ahmad
P304
P356
10.1158/1078-0432.CCR-11-0783
P407
P577
2011-10-25T00:00:00Z